GeoVax Labs Inc. (NASDAQ: GOVX) Publishes Its Efficacy Study of Modified Vaccine Ankara in the Nature Partner Journal (NPJ) Vaccines

GeoVax Labs Inc. (NASDAQ: GOVX) has announced the peer-reviewed animal efficacy trial’s publication in the Nature Partner Journal (NPJ) Vaccines. The study focuses on its modified vaccine Ankara (MVA).

MVA-VLP-SUDV vaccine combines attenuated vaccine vector’s immunogenicity 

The MVA-VLP-SUDV vaccine from GeoVax blends the benefits of a live attenuated vaccine vector’s immunogenicity with the genuine morphology of virus-like particles (VLPs). The enveloping glycoprotein GP and the structural protein VP40 are the only components that the vaccine expresses to cause the vaccine to produce self-assembling VLPs. Guinea pigs that received a single dose of the MVA-VLP-SUDV vaccine produced Fc-mediated protective effects and also attached and neutralizing antibodies specific to the SUDV. A second dosage of the vaccination increased these reactions. Upon treatment with a lethal dosage of SUDV, all immunized animals that had either received one/two vaccine dosages were shielded from demise and disease signs. These findings show the effectiveness of the MVA-VLP technology for use in containing outbreaks in emergency scenarios and single-dose therapy.

Mark J. Newman, GeoVax Chief Scientific Officer, stated, “The GeoVax MVA-VLP platform allows for the design of vaccines to present the immune system with multiple viral proteins in the conformation that mimics the actual virus. The resulting immune responses are broadly functional, involving both the antibody and T-cell effector function, resulting in optimal levels of efficacy, even with a single dose. These are ideal properties for vaccines that will support use in the general population. The next stage of testing involving nonhuman primates is nearing completion and we eagerly await those data.”

GeoVax MVA-VLP approach delivers a single highly effective vaccine 

CEO and Chairman of GeoVax David Dodd stated that the GeoVax MVA-VLP concept to deliver single, highly effective vaccines against infectious health threats globally is further validated by this paper. In a nonhuman primate model, the vaccine against the Zaire ebolavirus initially demonstrated 100% protection and single-dose safety. By including the Sudan ebolavirus in the vaccine lineup versus the hemorrhagic fever virus dangers, GeoVax is well-positioned to take the lead in this important area of healthcare protection.